BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
SMCI’s Strong AI Demand & Key Strategic Partnerships: Analyst Raises Expectations
Susquehanna analyst Mehdi Hosseini reiterated a Neutral rating on Super Micro Computer, Inc. (NASDAQ: SMCI),
